Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery disease ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Novo Nordisk's late stage diabetes candidate ... the company hopes to build on its success with semaglutide and its more convenient weekly dosing schedule. Novo is also developing semaglutide ...

Novo Nordisk has been on the hunt for differentiated ... Additional results showed that after dosing of semaglutide was stopped, the Lexicon drug mitigated weight regain and had positive effects ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday ... Surging demand for Novo's Ozempic, chemically known as semaglutide, has given rise to concerns about unregulated ...

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...

Novo Nordisk's hopes of heralding a new era of ... form of weight loss treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. It was hoped that the drug would ...

Novo Nordisk has quickly expanded ... that may be related to dosing errors of compounded injectable semaglutide products. As of the end of February, the FDA counted 455 reports of adverse events ...